There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Armata Pharmaceuticals (ARMP – Research Report) and Clearside Biomedical (CLSD – Research Report) with bullish sentiments.
Armata Pharmaceuticals (ARMP)
Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Armata Pharmaceuticals today and set a price target of $9.00. The company’s shares closed last Wednesday at $3.28, close to its 52-week low of $2.82.
According to TipRanks.com, Higgins is a 3-star analyst with an average return of
Currently, the analyst consensus on Armata Pharmaceuticals is a Moderate Buy with an average price target of $8.00, implying a 142.4% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $7.00 price target.
See today’s best-performing stocks on TipRanks >>
Clearside Biomedical (CLSD)
In a report released today, Andreas Argyrides from Wedbush reiterated a Buy rating on Clearside Biomedical, with a price target of $6.00. The company’s shares closed last Wednesday at $1.28, close to its 52-week low of $1.00.
According to TipRanks.com, Argyrides ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Clearside Biomedical with a $6.33 average price target, representing a 386.9% upside. In a report issued on November 3, JMP Securities also reiterated a Buy rating on the stock with a $7.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ARMP:
- Brookfield Announces Strong Third Quarter Results
- Wall Street Analysts Are Bullish on Top Technology Picks
- Waldencast plc, Announces Third Quarter Fiscal Year 2022 Financial Results
- TopBuild to Participate in Fireside Chat at Deutsche Bank’s 2022 Industrials Conference
- Wedbush Keeps Their Buy Rating on Unity Biotechnology (UBX)
